Long-term analysis of GRIPHON and its open-label extension in 953 selexipag-treated patients with pulmonary arterial hypertension: in 574 long-term patients (median follow-up 54 months), estimated 5-year survival was 74%; 39% stopped selexipag due to adverse events.
RCTn = 953
McLaughlin et al. Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension